The resistance of esophageal cancer cells to paclitaxel can be reduced by the knockdown of long noncoding RNA DDX11-AS1 through TAF1/TOP2A inhibition.
DDX11-AS1
TAF1
TOP2A
esophageal cancer
paclitaxel
resistance
Journal
American journal of cancer research
ISSN: 2156-6976
Titre abrégé: Am J Cancer Res
Pays: United States
ID NLM: 101549944
Informations de publication
Date de publication:
2019
2019
Historique:
received:
30
04
2019
accepted:
18
08
2019
entrez:
14
11
2019
pubmed:
14
11
2019
medline:
14
11
2019
Statut:
epublish
Résumé
Esophageal cancer (EC) is one of the most common malignancies in the world. The currently used chemotherapeutic drug for the treatment of EC is paclitaxel (PTX), the efficacy of which is affected by the development of drug resistance. The present study aims to define the role of the long noncoding RNA (lncRNA) DDX11-AS1 in the progression of EC with the involvement of PTX-resistant EC cells. First, EC and adjacent normal tissue samples were collected from 82 patients with EC, after which the expression levels of DDX11-AS1, TOP2A and TAF1 were determined. The results showed that DDX11-AS1, TOP2A and TAF1 were highly expressed in EC tissues, and there was a positive correlation between the expression levels of DDX11-AS1 and TOP2A. A PTX-resistant EC cell line was constructed. Next, we evaluated the effects of DDX11-AS1 and TOP2A on the resistance of EC cells to PTX, and the regulatory relationships between DDX11-AS1, TOP2A and TAF1 were investigated. DDX11-AS1 could promote TOP2A transcription via TAF1, and the knockdown of TOP2A or DDX11-AS1 could increase the sensitivity of EC cells to PTX. The effect of DDX11-AS1 on the growth of PTX-inhibited tumors was confirmed using a tumor formation assay in nude mice. It was verified that knocking down DDX11-AS1 reduced the expression level of TOP2A and inhibited tumor growth. In conclusion, our findings suggest that DDX11-AS1 knockdown results in reduced resistance of EC cells to PTX by inhibiting TOP2A transcription via TAF1. Therefore, DDX11-AS1 knockdown could be a promising therapeutic strategy for EC.
Types de publication
Journal Article
Langues
eng
Pagination
2233-2248Informations de copyright
AJCR Copyright © 2019.
Déclaration de conflit d'intérêts
None.
Références
Cancer Discov. 2011 Oct;1(5):391-407
pubmed: 22096659
Pathol Oncol Res. 2017 Jan;23(1):125-130
pubmed: 27571988
Endocr Relat Cancer. 2013 May 21;20(3):361-70
pubmed: 23533247
DNA Repair (Amst). 2018 Mar;63:1-9
pubmed: 29358095
Int J Cancer. 2009 Feb 1;124(3):644-52
pubmed: 19003983
Exp Ther Med. 2014 Jun;7(6):1578-1582
pubmed: 24926347
Oncotarget. 2016 May 3;7(18):25668-82
pubmed: 27015363
J Photochem Photobiol B. 2016 Aug;161:368-74
pubmed: 27295416
Mol Cell. 2004 Mar 26;13(6):867-78
pubmed: 15053879
Oncotarget. 2017 Aug 2;8(38):64191-64202
pubmed: 28969062
Oncotarget. 2017 Jul 4;8(27):44195-44202
pubmed: 28496001
Carcinogenesis. 2015 Nov;36(11):1255-62
pubmed: 26392258
J Cancer Res Ther. 2018 Sep;14(Supplement):S622-S627
pubmed: 30249878
World J Gastroenterol. 2015 Jul 14;21(26):7933-43
pubmed: 26185366
Free Radic Biol Med. 2012 Jan 15;52(2):473-87
pubmed: 22142471
Oncotarget. 2017 Jul 25;8(30):50071-50083
pubmed: 28637022
Biomed Pharmacother. 2017 Jun;90:897-905
pubmed: 28441715
J Clin Oncol. 2010 Feb 20;28(6):984-90
pubmed: 20038724
Oncol Rep. 2016 Oct;36(4):1861-7
pubmed: 27498905
J UOEH. 2011 Sep 1;33(3):205-16
pubmed: 21913377
Scand J Gastroenterol. 2012 Jul;47(7):802-8
pubmed: 22545578
Cell Rep. 2017 Dec 19;21(12):3483-3497
pubmed: 29262328
Nat Med. 2015 Nov;21(11):1253-61
pubmed: 26540387
Zhonghua Bing Li Xue Za Zhi. 2011 May;40(5):351-4
pubmed: 21756837
Breast Cancer Res Treat. 2008 Mar;108(2):183-90
pubmed: 17468948
Biochem Pharmacol. 2009 Jul 15;78(2):178-83
pubmed: 19464433
Int J Gynecol Cancer. 2016 Feb;26(2):325-30
pubmed: 26588239
Biosci Rep. 2017 Oct 17;37(5):null
pubmed: 28939763
Biochim Biophys Acta Mol Basis Dis. 2018 Jan;1864(1):197-207
pubmed: 29045811
Clin Epigenetics. 2018 Feb 27;10(1):26
pubmed: 30359298
Mol Carcinog. 2016 Dec;55(12):2095-2105
pubmed: 26756568
Gastroenterology. 2018 Jan;154(2):437-451
pubmed: 29037469
Mol Cell. 2016 Aug 4;63(3):397-407
pubmed: 27477908
Radiology. 2014 Jan;270(1):141-8
pubmed: 23985274
Genom Data. 2017 Feb 05;12:4-6
pubmed: 28224081
Biomed Res Int. 2015;2015:381602
pubmed: 25695068
Breast Cancer Res. 2016 Aug 08;18(1):83
pubmed: 27503504
J Clin Invest. 2016 Aug 1;126(8):2775-82
pubmed: 27479746
Lung Cancer. 2014 Aug;85(2):110-5
pubmed: 24906504
Int J Clin Exp Pathol. 2015 Oct 01;8(10):13687-94
pubmed: 26722596
Sci Rep. 2018 Mar 29;8(1):5395
pubmed: 29599483
World J Surg. 2015 Sep;39(9):2282-8
pubmed: 25952691
Dis Esophagus. 2017 Jan 1;30(1):1-7
pubmed: 26918692
Curr Opin Genet Dev. 2015 Feb;30:25-31
pubmed: 25622247
Cell Mol Life Sci. 2016 Aug;73(16):3205-15
pubmed: 26879577